Evidence map›Paper›PMID 36224377›Full record

Trial reportProstate cancer and prostatic diseases2023

Incidence and survival of castration-resistant prostate cancer patients with visceral metastases: results from the Dutch CAPRI-registry.

Gijs P A van den Bergh, Malou C P Kuppen, Hans M Westgeest, Niven Mehra, Winald R Gerritsen, Katja K H Aben, Inge M van Oort, Reindert J A van Moorselaar, Diederik M Somford, Alfonsus J M van den Eertwegh and 3 more

Open access · bronzeAbstract readClinical Trial
PubMed Publisher
In one paragraph

Trial report in Prostate cancer and prostatic diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 14 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Review
  5. Prognostic value of [Annals of medicine · 2024
    Article
  6. Review
  7. Review
  8. Impact ofTheranostics · 2024
    Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 9 institutions in 1 country.

Gijs P A van den Bergh *Institute for Medical Technology Assessment, Erasmus School of Health Policy & Management, Erasmus University Rotterdam, Rotterdam, The Netherlands. vandenbergh@eshpm.eur.nl.ORCID http://orcid.org/0000-0001-6442-4505
Malou C P Kuppen *Institute for Medical Technology Assessment, Erasmus School of Health Policy & Management, Erasmus University Rotterdam, Rotterdam, The Netherlands. kuppen@eshpm.eur.nl.ORCID http://orcid.org/0000-0001-8908-1684
Hans M WestgeestDepartment of Internal Medicine, Amphia Hospital, Breda, The Netherlands.
Niven MehraDepartment of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands.ORCID http://orcid.org/0000-0002-4794-1831
Winald R GerritsenDepartment of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands.
Katja K H AbenDepartment for Health Evidence, Radboud University Medical Center, Nijmegen, The Netherlands.
Inge M van OortDepartment of Urology, Radboud University Medical Center, Nijmegen, The Netherlands.ORCID http://orcid.org/0000-0002-8002-1869
Reindert J A van MoorselaarDepartment of Urology, Amsterdam UMC, Vrije Universiteit, Amsterdam, The Netherlands.
Diederik M SomfordDepartment of Urology, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands.ORCID http://orcid.org/0000-0002-5277-6586
Alfonsus J M van den EertweghDepartment of Medical Oncology, Amsterdam UMC location Vrije Universiteit Amsterdam, The Netherlands; Cancer Center Amsterdam, Amsterdam, The Netherlands.
André M BergmanDivision of Internal Medicine (MOD) and Oncogenomics, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.ORCID http://orcid.org/0000-0001-5223-2549
Alphonsus C M van den BerghDepartment of Radiation Oncology, University Medical Center Groningen, Groningen, The Netherlands.
Carin A Uyl-de GrootInstitute for Medical Technology Assessment, Erasmus School of Health Policy & Management, Erasmus University Rotterdam, Rotterdam, The Netherlands.
Radboud University Nijmegen · NLErasmus MC · NLAmphia Ziekenhuis · NLAmsterdam Neuroscience · NLAmsterdam University Medical Centers · NLCanisius-Wilhelmina Ziekenhuis · NLErasmus University Rotterdam · NLThe Netherlands Cancer Institute · NLUniversity Medical Center Groningen · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe objective of this real-world population study is to investigate incidence and treatment of visceral metastases (VMs) in castration resistant prostate cancer (CRPC) patients and their survival.

methodsCRPC-patients in the CAPRI-registry between 2010 and 2016 were included in the analyses and followed till 2017. Outcomes were proportion of patients radiologically screened for VMs and proportion of patients with VMs at CRPC-diagnosis and at the start of every treatment line. Groups have been created based on location of VMs (lung, liver, or both) at date of first VM diagnosis. The outcome for these groups was overall survival (OS). Statistics included descriptive analyses, Kaplan-Meier method, and Cox proportional hazard regression analysis for survival analyses.

resultsOf 3602 patients from the CAPRI registry, 457 patients (12.7%) were diagnosed with VMs during follow-up: 230 patients with liver, 161 with lung, and 66 with both liver and lung metastases. The proportion of patients radiologically screened for VMs increased per treatment line as did the occurrence rate of VMs. However, 80% of patients at CRPC diagnosis to 40% in the 6th line were not screened for VMs at the start of a systemic treatment. Median OS was 8.6 months for patients with liver, 18.3 with lung and 10.9 with both liver and lung metastases (p < 0.001) from date of first VM diagnosis. After correction for prognostic factors patients with lung metastases had significantly better OS than patients with liver metastases (HR 0.650, p = 0.001).

conclusionThis real-world analysis showed that despite the increased rate of radiological staging during follow-up, still 80% to 40% of the patients (CRPC diagnosis to 6th treatment line respectively) were not screened for VMs at the start of a systemic treatment. VMs and location of VMs are key prognostic patient characteristics, impacts survival and have implications for treatment decisions, so routine staging of CRPC-patients is warranted. CLINICAL TRIAL IDENTIFICATION: The CAPRI study is registered in the Dutch Trial Registry as NL3440 (NTR3591).

Indexed as

Lung NeoplasmsProstatic Neoplasms, Castration-ResistantHumansIncidenceMalePrognosisRegistriesRetrospective Studies

Identifiers

PMID36224377
OpenAlexW4304688635

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.